Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 828427, 8 pages
http://dx.doi.org/10.1155/2015/828427
Research Article

Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPARγ in SHRs

1Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
2Department of Cardiology, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China

Received 2 March 2015; Revised 15 July 2015; Accepted 11 October 2015

Academic Editor: Honglin Luo

Copyright © 2015 Wei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. C. Simões E Silva and J. T. Flynn, “The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease,” Pediatric Nephrology, vol. 27, no. 10, pp. 1835–1845, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, “The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease,” Pharmacological Reviews, vol. 59, no. 3, pp. 251–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Z. Duan, C. Y. Ivashchenko, M. G. Usher, and R. M. Mortensen, “PPAR-gamma in the cardiovascular system,” PPAR Research, vol. 2008, Article ID 745804, 10 pages, 2008. View at Publisher · View at Google Scholar
  4. A. Sugawara, A. Uruno, K. Matsuda et al., “Effects of PPARγ agonists against vascular and renal dysfunction,” Current Molecular Pharmacology, vol. 5, no. 2, pp. 248–254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Q. Zhang, Y.-M. Yang, and G.-Y. Yu, “Effects of gastrodin injection on blood pressure and vasoactive substances in treatment of old patients with refractory hypertension: a randomized controlled trial,” Journal of Chinese Integrative Medicine, vol. 6, no. 7, pp. 695–699, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Shu, C. Chen, D.-P. Zhang et al., “Gastrodin protects against cardiac hypertrophy and fibrosis,” Molecular and Cellular Biochemistry, vol. 359, no. 1-2, pp. 9–16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Li, K.-J. Wang, J.-J. Chen, and J. Zhou, “Phenolic compounds from the rhizomes of Gastrodia elata,” Journal of Asian Natural Products Research, vol. 9, no. 4, pp. 373–377, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. X.-D. Yang, J. Zhu, R. Yang, J.-P. Liu, L. Li, and H.-B. Zhang, “Phenolic constituents from the rhizomes of Gastrodia elata,” Natural Product Research, vol. 21, no. 2, pp. 180–186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. Y.-Q. Xiao, L. Li, X.-L. You, B.-L. Bian, X.-M. Liang, and Y.-T. Wang, “A new compound from Gastrodia elata Blume,” Journal of Asian Natural Products Research, vol. 4, no. 1, pp. 73–79, 2002. View at Google Scholar · View at Scopus
  11. L. M. Ojemann, W. L. Nelson, D. S. Shin, A. O. Rowe, and R. A. Buchanan, “Tian ma, an ancient Chinese herb, offers new options for the treatment of epilepsy and other conditions,” Epilepsy and Behavior, vol. 8, no. 2, pp. 376–383, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Liu, X. Tang, J. Pei, L. Zhang, F. Liu, and K. Li, “Gastrodin interaction with human fibrinogen: anticoagulant effects and binding studies,” Chemistry—A European Journal, vol. 12, no. 30, pp. 7807–7815, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. C. R. Esther Jr., E. M. Marino, T. E. Howard et al., “The critical role of tissue angiotensin-converting enzyme as revealed by genetargeting in mice,” The Journal of Clinical Investigation, vol. 99, no. 10, pp. 2375–2385, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, pp. 239–263, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Marchesi and E. L. Schiffrin, “Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects,” Journal of the American Society of Hypertension, vol. 2, no. 4, pp. 227–238, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. D. Giles and G. E. Sander, “Effects of thiazolidinediones on blood pressure,” Current Hypertension Reports, vol. 9, no. 4, pp. 332–337, 2007. View at Google Scholar
  17. P. A. Sarafidis and A. N. Lasaridis, “Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect,” American Journal of Hypertension, vol. 19, no. 6, pp. 646–653, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Dormandy, B. Charbonnel, D. J. A. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Schupp, M. Clemenz, R. Gineste et al., “Molecular characterization of new selective peroxisome proliferator- activated receptor γ modulators with angiotensin receptor blocking activity,” Diabetes, vol. 54, no. 12, pp. 3442–3452, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. R. A. Sanchez, L. D. Masnatta, C. Pesiney, P. Fischer, and A. J. Ramirez, “Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives,” Journal of Hypertension, vol. 26, no. 12, pp. 2393–2398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Imayama, T. Ichiki, K. Inanaga et al., “Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ,” Cardiovascular Research, vol. 72, no. 1, pp. 184–190, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. E. R. Blasi, J. Heyen, M. Hemkens, A. McHarg, C. M. Ecelbarger, and S. Tiwari, “Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats,” PPAR Research, vol. 2009, Article ID 237865, 13 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus